Therapeutic Benefits of Tocilizumab Vary in Different Organs of a Patient with AA Amyloidosis

Table 1

Laboratory findings on admission.

Urinalysis
Protein	1+
Occult blood	1+
Glucose	−
Urine sediment
WBC	1–4	/HPF
RBC	1–4	/HPF
Granular casts	1+	/LPF
Complete blood counts
WBC	13600	/mm^3
RBC	355	×10^4/mm^3
Hemoglobin	9.6	g/dL
Hematocrit	29.9	%
Platelets	81.9	×10^4/mm^3
Biochemistry
CRP	3.4	mg/dL
SAA	32.3	μg/mL
Total protein	5.8	g/dL
Albumin	3.2	g/dL
Glucose	94	mg/dL
Uric acid	9.6	mg/dL
BUN	55	mg/dL
Scr	4.35	mg/dL
eGFR	8.6	mL/min/1.73 m^2
Sodium	139	mEq/L
Potassium	4.8	mEq/L
Chloride	106	mEq/L
Serum -MG	11.4	mg/L
Urinary -MG	4189	μg/L
Immunology
RF	3.4	IU/mL
ANA	−
Anti-CCP Ab	3.4	U/mL
MMP3	322	ng/mL
Complement	37	U/mL
C3	62.4	mg/dL
C4	20.6	mg/dL
IgA	269.2; 2	mg/dL
IgG	1119.9	mg/dL
IgM	76.8	mg/dL
Endocrinology
HbA1c	6.2	%
BNP	3002.5	pg/mL

RBC: red blood cell; WBC: white blood cell; HPF: high-power field; CRP: C-reactive protein; SAA: serum amyloid A protein; BUN: blood urea nitrogen; Scr: serum creatinine; eGFR: estimated glomerular filtration ratio; MG: -microglobulin; HbA1c: haemoglobin A1c; BNP: B-type natriuretic peptide; RF: rheumatoid factor; ANA: antinuclear antibody; anti-CCP Ab: antibodies against cyclic citrullinated peptide; MMP3: matrix metalloproteinase 3; Ig: immunoglobulin.